文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症消化、代谢与肾脏急症

大剂量埃索美拉唑作为抗炎剂治疗脓毒症的多国随机试验

A Multinational Randomized Trial of Mega-Dose Esomeprazole as Anti-Inflammatory Agent in Sepsis.
PubMed 文献 · Crit Care Med · 2025-05-29
一句话结论在脓毒症或脓毒性休克患者中,大剂量埃索美拉唑未减少器官功能障碍或其他患者相关或生物学次要结局。

这项多国、随机、双盲、安慰剂对照试验在3个国家17个ICU或急诊科纳入307例成人脓毒症或脓毒性休克患者,随机分为大剂量埃索美拉唑(1024 mg,72小时)组148例和安慰剂组159例。主要终点为至第10天的平均每日SOFA评分,埃索美拉唑组中位数5(IQR 3-9),安慰剂组5(IQR 3-8),风险差0.1(95%CI -0.8至1.0,p>0.99)。次要结局(无抗生素天数、第28天无ICU天数、全因死亡率)均无差异。患者外周血单核细胞经Toll样受体激动剂激活后呈促炎表型,埃索美拉唑治疗未影响该表型。

要点

  • 在成人脓毒症或脓毒性休克患者中,大剂量埃索美拉唑(1024 mg,72小时)组与安慰剂组至第10天平均每日SOFA评分中位数均为5(IQR分别为3-9和3-8),风险差0.1(95%CI -0.8至1.0,p>0.99)。
  • 无抗生素天数、第28天无ICU天数及全因死亡率等次要结局在埃索美拉唑组与安慰剂组间均无差异。
  • 患者外周血单核细胞经Toll样受体激动剂激活后呈促炎表型,该表型未受埃索美拉唑治疗影响。
  • 该多国随机双盲安慰剂对照试验纳入307例患者(埃索美拉唑组148例,安慰剂组159例),54%为脓毒性休克,随机时SOFA评分中位数7。

适用人群与场景

  • 成人脓毒症或脓毒性休克患者,来自3个国家17个ICU或急诊科。
  • 共随机307例:埃索美拉唑组148例,安慰剂组159例;平均年龄71岁;166例(54%)为脓毒性休克;随机时SOFA评分中位数7。

处置流程与药物剂量

  • 埃索美拉唑组:大剂量埃索美拉唑1024 mg,72小时内给药;安慰剂组给予安慰剂。

研究设计与关键结果

  • 研究设计:多国、随机、双盲、安慰剂对照临床试验,3个国家17个ICU或急诊科,纳入307例成人脓毒症或脓毒性休克患者。
  • 主要终点:至第10天平均每日SOFA评分中位数,埃索美拉唑组5(IQR 3-9)vs 安慰剂组5(IQR 3-8),风险差0.1(95%CI -0.8至1.0),p>0.99。
  • 机制研究:患者外周血单核细胞经Toll样受体激动剂激活后呈促炎表型,埃索美拉唑治疗未影响该表型。

证据类型、等级与局限

  • 证据类型:多国随机双盲安慰剂对照临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在成人脓毒症或脓毒性休克患者中,大剂量埃索美拉唑1024 mg(72小时)未减少器官功能障碍(至第10天平均每日SOFA评分中位数5 vs 5,风险差0.1,95%CI -0.8至1.0,p>0.99),未改变无抗生素天数、第28天无ICU天数及全因死亡率。
  • 患者外周血单核细胞经Toll样受体激动剂激活后的促炎表型未受埃索美拉唑治疗影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Proton pump inhibitors have dose-dependent immunomodulatory effects. We tested the hypothesis that mega-dose esomeprazole therapy would reduce organ dysfunction in patients with sepsis or septic shock.

DESIGN: A multinational, randomized, double-blind, placebo-controlled clinical trial.

SETTING: Seventeen ICUs or emergency departments in three countries.

PATIENTS: Adult patients with sepsis or septic shock.

INTERVENTIONS: Mega-dose (1024 mg) esomeprazole or placebo over a 72-hour period.

MEASUREMENTS AND MAIN RESULTS: The primary outcome was mean daily Sequential Organ Failure Assessment (SOFA) score to day 10. Secondary outcomes included antibiotics-free days, ICU-free days at day 28, and all-cause mortality. We also conducted a mechanistic study of the in vitro effects of esomeprazole in sepsis. We randomized 307 patients and assigned 148 to esomeprazole and 159 to placebo. Mean age was 71 years; 166 patients (54%) had septic shock and median SOFA score at randomization was 7. The median mean daily SOFA score in the first 10 days post-randomization was 5 (interquartile range [IQR], 3-9) in the esomeprazole group and 5 (IQR, 3-8) in the placebo group (risk difference, 0.1; 95% CI, -0.8 to 1.0; p > 0.99). No differences were observed in secondary outcomes. Monocytes isolated from patients' peripheral blood and activated with a toll-like receptor agonist exhibited a pro-inflammatory phenotype, which was not affected by esomeprazole therapy.

CONCLUSIONS: Among patients with sepsis or septic shock, mega-dose esomeprazole did not reduce organ dysfunction or other patient-related or biological secondary outcomes.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Monti G, Carta S, Kotani Y, et al. A Multinational Randomized Trial of Mega-Dose Esomeprazole as Anti-Inflammatory Agent in Sepsis. Crit Care Med. 2025. PMID: 40439536. doi:10.1097/CCM.0000000000006720

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。